High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer
<b>Background/Objectives:</b> This study aimed to determine whether the expression levels of <i>GPAT4</i> and <i>SLC7A11</i> are associated with survival outcomes and platinum resistance in epithelial ovarian cancer (EOC) patients. <b>Methods:</b> We a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/7/1664 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766023099580416 |
|---|---|
| author | Ping Yu Chunliang Shang Zhongyu Liu Yuan Li Tianhui He Yuan Xue Jian Lin Yuan Li Yu Wu Tong Liu Hongyan Guo |
| author_facet | Ping Yu Chunliang Shang Zhongyu Liu Yuan Li Tianhui He Yuan Xue Jian Lin Yuan Li Yu Wu Tong Liu Hongyan Guo |
| author_sort | Ping Yu |
| collection | DOAJ |
| description | <b>Background/Objectives:</b> This study aimed to determine whether the expression levels of <i>GPAT4</i> and <i>SLC7A11</i> are associated with survival outcomes and platinum resistance in epithelial ovarian cancer (EOC) patients. <b>Methods:</b> We analyzed the medical records of EOC patients. EOC samples obtained during surgery were stained for <i>GPAT4</i> and <i>SLC7A11</i>. Cox regression and Kaplan—Meier analyses were performed to assess the impact of <i>GPAT4</i> and <i>SLC7A11</i> expression on overall survival (OS). <b>Results:</b> We found that <i>GPAT4</i> and <i>SLC7A11</i> expression levels were greater in platinum-resistant ovarian cancer tissues than in platinum-sensitive ovarian cancer tissues. High expression of both <i>GPAT4</i> and <i>SLC7A11</i> was associated with an increased risk of platinum resistance compared with low expression of both factors. High expression of both SLC7A11 and GPAT4 was independently correlated with poor OS, highlighting the significance of this integrated metric as a prognostic factor in ovarian cancer. The <i>GPAT</i> inhibitor (GPAT-IN-1) and an <i>SLC7A11</i> inhibitor (erastin) attenuated platinum resistance in ovarian cancer cells, and their combined application increased cytotoxicity. Furthermore, the combination of GPAT-IN-1, erastin, and cisplatin significantly improved the chemotherapeutic effects on platinum-resistant ovarian cancer cells. <b>Conclusions:</b> High expression of both <i>SLC7A11</i> and <i>GPAT4</i> is related to platinum resistance in EOC patients. The high expression of both <i>SLC7A11</i> and <i>GPAT4</i> serves as an important independent prognostic factor and indicates potential therapeutic targets for patients with platinum-resistant EOC. |
| format | Article |
| id | doaj-art-696368dec42d4e259302151749ef4b91 |
| institution | DOAJ |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-696368dec42d4e259302151749ef4b912025-08-20T03:04:42ZengMDPI AGBiomedicines2227-90592025-07-01137166410.3390/biomedicines13071664High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian CancerPing Yu0Chunliang Shang1Zhongyu Liu2Yuan Li3Tianhui He4Yuan Xue5Jian Lin6Yuan Li7Yu Wu8Tong Liu9Hongyan Guo10Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaReproductive Medicine Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, ChinaDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaCenter of Basic Medical Research, Institute of Medical Innovation and Research, Cancer Center of Peking University Third Hospital, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China<b>Background/Objectives:</b> This study aimed to determine whether the expression levels of <i>GPAT4</i> and <i>SLC7A11</i> are associated with survival outcomes and platinum resistance in epithelial ovarian cancer (EOC) patients. <b>Methods:</b> We analyzed the medical records of EOC patients. EOC samples obtained during surgery were stained for <i>GPAT4</i> and <i>SLC7A11</i>. Cox regression and Kaplan—Meier analyses were performed to assess the impact of <i>GPAT4</i> and <i>SLC7A11</i> expression on overall survival (OS). <b>Results:</b> We found that <i>GPAT4</i> and <i>SLC7A11</i> expression levels were greater in platinum-resistant ovarian cancer tissues than in platinum-sensitive ovarian cancer tissues. High expression of both <i>GPAT4</i> and <i>SLC7A11</i> was associated with an increased risk of platinum resistance compared with low expression of both factors. High expression of both SLC7A11 and GPAT4 was independently correlated with poor OS, highlighting the significance of this integrated metric as a prognostic factor in ovarian cancer. The <i>GPAT</i> inhibitor (GPAT-IN-1) and an <i>SLC7A11</i> inhibitor (erastin) attenuated platinum resistance in ovarian cancer cells, and their combined application increased cytotoxicity. Furthermore, the combination of GPAT-IN-1, erastin, and cisplatin significantly improved the chemotherapeutic effects on platinum-resistant ovarian cancer cells. <b>Conclusions:</b> High expression of both <i>SLC7A11</i> and <i>GPAT4</i> is related to platinum resistance in EOC patients. The high expression of both <i>SLC7A11</i> and <i>GPAT4</i> serves as an important independent prognostic factor and indicates potential therapeutic targets for patients with platinum-resistant EOC.https://www.mdpi.com/2227-9059/13/7/1664ferroptosis<i>GPAT4</i><i>SLC7A11</i>platinum resistanceovarian cancer |
| spellingShingle | Ping Yu Chunliang Shang Zhongyu Liu Yuan Li Tianhui He Yuan Xue Jian Lin Yuan Li Yu Wu Tong Liu Hongyan Guo High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer Biomedicines ferroptosis <i>GPAT4</i> <i>SLC7A11</i> platinum resistance ovarian cancer |
| title | High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer |
| title_full | High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer |
| title_fullStr | High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer |
| title_full_unstemmed | High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer |
| title_short | High Co-Expression of <i>GPAT4</i> and <i>SLC7A11</i> as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer |
| title_sort | high co expression of i gpat4 i and i slc7a11 i as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer |
| topic | ferroptosis <i>GPAT4</i> <i>SLC7A11</i> platinum resistance ovarian cancer |
| url | https://www.mdpi.com/2227-9059/13/7/1664 |
| work_keys_str_mv | AT pingyu highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT chunliangshang highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT zhongyuliu highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT yuanli highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT tianhuihe highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT yuanxue highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT jianlin highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT yuanli highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT yuwu highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT tongliu highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer AT hongyanguo highcoexpressionofigpat4iandislc7a11iasapredictorofplatinumresistanceandpoorprognosisinpatientswithepithelialovariancancer |